For the first time, the U.S. Food and Drug Administration has provided draft guidance clarifying how benefit-risk determinations are made during premarket review of certain medical devices.
Read the complete post at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm267995.htm
Posted
Mon, Aug 15 2011 10:00 AM
by
Food and Drug Administration--Press Releases